CRIS Share Price

Open 1.74 Change Price %
High 1.74 1 Day -0.01 -0.58
Low 1.69 1 Week 0.04 2.41
Close 1.70 1 Month -0.97 -36.33
Volume 465169 1 Year -0.01 -0.58
52 Week High 3.72
52 Week Low 1.47
CRIS Important Levels
Resistance 2 1.75
Resistance 1 1.73
Pivot 1.71
Support 1 1.67
Support 2 1.65
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CMCSA 40.34 0.02%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
BCRX 6.73 31.19%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LIME 2.15 22.16%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Curis, Inc. (NASDAQ: CRIS)

CRIS Technical Analysis 5
As on 25th May 2017 CRIS Share Price closed @ 1.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.46 & Strong Sell for SHORT-TERM with Stoploss of 2.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRIS Target for May
1st Target up-side 2.68
2nd Target up-side 2.86
3rd Target up-side 3.04
1st Target down-side 2.16
2nd Target down-side 1.98
3rd Target down-side 1.8
CRIS Other Details
Segment EQ
Market Capital 288233760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.curis.com
CRIS Address
CRIS
4 Maguire Road
Lexington, MA 02421
United States
Phone: 617-503-6500
Fax: 617-503-6501
CRIS Latest News
Interactive Technical Analysis Chart Curis, Inc. ( CRIS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Curis, Inc.
CRIS Business Profile
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).